Study record at a glance
| Study ID | dmx-1001-aud |
|---|---|
| Design | Planned clinical development: the company describes an alcohol-interaction study supporting a planned Phase 2 trial in alcohol use disorder |
| Condition / topic | Alcohol use disorder |
| Population | People with alcohol use disorder are the intended Phase 2 population described in the company announcement |
| Sample size | Not stated for the planned alcohol use disorder trial in the cited announcement |
| Comparator | Not stated for the planned alcohol use disorder trial in the cited announcement |
| Follow-up | Not stated for the planned alcohol use disorder trial in the cited announcement |
| Outcome focus | Clinical development of DMX-1001, an oral noribogaine candidate, for alcohol use disorder; no registered outcome set is cited in the announcement |
What it suggests
DemeRx announced FDA acceptance of its Investigational New Drug application in April 2026, permitting the described development program to proceed toward further study
What it cannot establish
IND acceptance is not evidence of efficacy or approval. The announcement cannot establish the final trial design, comparative benefit, long-term safety, or whether the planned study will begin as anticipated
Recruitment relevance
Enrollment has not opened in the current editorial evidence. An accepted IND does not mean that a trial is recruiting; check a future registry record or sponsor instructions before seeking participation
Do not travel, discontinue medication, or change care based on this summary. The sponsor and the current primary source govern participation decisions.
How this summary was framed
This record reports the design and registered or officially announced research question before interpretation. Unknown sample, comparator, follow-up, and outcome details remain marked as unknown. The Atlas does not infer results from recruitment status, regulatory acceptance, funding, or study completion.